Interaction Between Determinants Governing Urine Volume in Patients With ADPKD on Tolvaptan and its Impact on Quality of Life-Reference-Cited by-同舟云学术

Interaction Between Determinants Governing Urine Volume in Patients With ADPKD on Tolvaptan and its Impact on Quality of Life

Published:2023-08 Issue:8 Volume:8 Page:1616-1626
ISSN:2468-0249
Container-title:Kidney International Reports
language:en
Short-container-title:Kidney International Reports

Author:

Todorova Polina,Arjune Sita,Hendrix Claudia,Oehm Simon,Schmidt Johannes,Krauß Denise,Burkert Katharina,Burst Volker Rolf,Benzing Thomas,Boehm Volker,Grundmann Franziska,Müller Roman-Ulrich

Publisher

Elsevier BV

Subject

Nephrology

Reference33 articles.

1. Renal replacement therapy for autosomal dominant polycystic kidney disease (ADPKD) in Europe: prevalence and survival--an analysis of data from the ERA-EDTA Registry;Spithoven;Nephrol Dial Transplant,2014

2. Overweight and obesity and progression of ADPKD;Nowak;Clin J Am Soc Nephrol,2021

3. Autosomal dominant polycystic kidney disease: core curriculum 2016;Chebib;Am J Kidney Dis,2016

4. Management of autosomal-dominant polycystic kidney disease-state-of-the-art;Muller;Clin Kidney J,2018

5. Tolvaptan in patients with autosomal dominant polycystic kidney disease;Torres;N Engl J Med,2012

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Primer for Utilizing Deep Learning and Abdominal MRI Imaging Features to Monitor Autosomal Dominant Polycystic Kidney Disease Progression;Biomedicines;2024-05-20

2. Investigational agents for autosomal dominant polycystic kidney disease: preclinical and early phase study insights;Expert Opinion on Investigational Drugs;2024-04-21

3. What is the Appropriate Dose of Tolvaptan in ADPKD?;Kidney International Reports;2024-04